Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.

A Comprehensive Study on Hemostasis in CAPD Patients Treated with Erythropoietin

A Vitamin E-Coated Polysulfone Membrane Reduces Serum Levels of Inflammatory Markers and Resistance to Erythropoietin-Stimulating Agents in Hemodialysis Patients: Results of a Randomized Cross-Over Multicenter Trial

Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming

Erythropoietin Effect on Complement Activation in Chronic Kidney Disease

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients

Effects of Recombinant Human Erythropoietin on Platelet Activation in Acute Myocardial Infarction: Results of a Double-Blind, Placebo-Controlled, Randomized Trial

Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.

Effects of Long-Term Treatment with Simvastatin on Some Hemostatic Parameters in Continuous Ambulatory Peritoneal Dialysis Patients

Efficacy,safety and Tolerance of Continuous Erythropoietin Receptor Activator Intravenous Administration on Anemia Correction in Dialysis Patients with Chronic Renal Anemia

Effects of erythropoietin on risk of thrombus in patients with chronic heart failure

Protective Effect of Platelets Transfusion During Extracorporeal Circulation

Effects of Erythropoietin on the Lipid Metabolism in Pre-dialysis Patients

Effect of Plasma of Patients with Different Dialysis Modes on Marrow Erythroid Progenitors of Mice

Effect of Treatment with Recombinant Human Erythropoietin on Peripheral Hemodynamics and Oxygenation

Changes of the peripheral blood endothelial progenitor cells in peritoneal dialysis patients and its impact factors

Effect of Epoetin Alfa on Left Ventricular Hypertrophy in Pre-dialysis Patients

The Effects of Citrate Dialysate in Hemodialysis on Polymorphonuclear Elastase Interaction with Tissue Factor and Its Inhibitor.

Pharmacokinetics of Intravenous Teicoplanin in Peritoneal Dialysis Patients with Respiratory Infections.

Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients

Randomized,double-blind,controlled Cllinical Trial of Effects of Recombinant Human Erythropoietin on the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Subjects